Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review

Detalhes bibliográficos
Autor(a) principal: Cruz, Júlia Niehues da
Data de Publicação: 2017
Outros Autores: Magro, Débora Delwing Dal, Lima, Daniela Delwing de, Cruz, José Geraldo Pereira da
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/131411
Resumo: Membrane/lipid rafts (MLRs) are plasmalemmal microdomains that are essential for neuronal signaling and synaptic development/stabilization. Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (statins) can disable the N-methyl-D-aspartate (NMDA) receptor through disruption of MLRs and, in turn, decrease NMDA-mediated anxiety. This hypothesis will contribute to understanding the critical roles of simvastatin in treating anxiety via the NMDA receptor.
id USP-31_6cbb60195c2561f39abcea3c1780fa72
oai_identifier_str oai:revistas.usp.br:article/131411
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature reviewAnxiolytic effectsMembrane/lipid raftsN-methyl-D-aspartateSimvastatin.Membrane/lipid rafts (MLRs) are plasmalemmal microdomains that are essential for neuronal signaling and synaptic development/stabilization. Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (statins) can disable the N-methyl-D-aspartate (NMDA) receptor through disruption of MLRs and, in turn, decrease NMDA-mediated anxiety. This hypothesis will contribute to understanding the critical roles of simvastatin in treating anxiety via the NMDA receptor.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2017-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/13141110.1590/s2175-97902017000116102Brazilian Journal of Pharmaceutical Sciences; Vol. 53 Núm. 1 (2017); e16102-Brazilian Journal of Pharmaceutical Sciences; v. 53 n. 1 (2017); e16102-Brazilian Journal of Pharmaceutical Sciences; Vol. 53 No. 1 (2017); e16102-2175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/131411/127791Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessCruz, Júlia Niehues daMagro, Débora Delwing DalLima, Daniela Delwing deCruz, José Geraldo Pereira da2017-04-20T20:28:50Zoai:revistas.usp.br:article/131411Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2017-04-20T20:28:50Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review
title Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review
spellingShingle Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review
Cruz, Júlia Niehues da
Anxiolytic effects
Membrane/lipid rafts
N-methyl-D-aspartate
Simvastatin.
title_short Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review
title_full Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review
title_fullStr Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review
title_full_unstemmed Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review
title_sort Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review
author Cruz, Júlia Niehues da
author_facet Cruz, Júlia Niehues da
Magro, Débora Delwing Dal
Lima, Daniela Delwing de
Cruz, José Geraldo Pereira da
author_role author
author2 Magro, Débora Delwing Dal
Lima, Daniela Delwing de
Cruz, José Geraldo Pereira da
author2_role author
author
author
dc.contributor.author.fl_str_mv Cruz, Júlia Niehues da
Magro, Débora Delwing Dal
Lima, Daniela Delwing de
Cruz, José Geraldo Pereira da
dc.subject.por.fl_str_mv Anxiolytic effects
Membrane/lipid rafts
N-methyl-D-aspartate
Simvastatin.
topic Anxiolytic effects
Membrane/lipid rafts
N-methyl-D-aspartate
Simvastatin.
description Membrane/lipid rafts (MLRs) are plasmalemmal microdomains that are essential for neuronal signaling and synaptic development/stabilization. Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (statins) can disable the N-methyl-D-aspartate (NMDA) receptor through disruption of MLRs and, in turn, decrease NMDA-mediated anxiety. This hypothesis will contribute to understanding the critical roles of simvastatin in treating anxiety via the NMDA receptor.
publishDate 2017
dc.date.none.fl_str_mv 2017-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/131411
10.1590/s2175-97902017000116102
url https://www.revistas.usp.br/bjps/article/view/131411
identifier_str_mv 10.1590/s2175-97902017000116102
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/131411/127791
dc.rights.driver.fl_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 53 Núm. 1 (2017); e16102-
Brazilian Journal of Pharmaceutical Sciences; v. 53 n. 1 (2017); e16102-
Brazilian Journal of Pharmaceutical Sciences; Vol. 53 No. 1 (2017); e16102-
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222912892895232

Registros relacionados